Inhibin B in stromal-cell ovarian tumors
https://doi.org/10.17650/2313-805X-2020-7-1-32-37
Abstract
Background. Tumors of stroma of the sex cord include a family of tumors that are diverse in structure and biological characteristics, including hormone-active ovarian tumors, such as granulosa cell tumor (GCT) of the ovary and a tumor from Sertoli–Leydig cells. For these types of tumors, of particular importance is the analysis of biochemical markers, among which the most promising is inhibin B.
The objective of the study. Comparative analysis of inhibin B levels in the blood serum of patients with stromal cell tumors and other types malignancies.
Materials and methods. 64 patients with primary ovarian tumors were examined: 31 – GCT of the ovary, 16 – tumors from Sertoli–Leydig cells, 17 – adenocarcinomas. Comparison group – 20 patients with malignant tumors of other localizations, control – 74 healthy women and 37 patients with benign ovarian tumors. Inhibin B was determined in blood serum using the standardized Inhibin B Gen II ELISA (Beckman Coulter, USA) immunoassay.
Results. The analysis of inhibin B levels in last days of the luteal phase, show an increase of marker level in patients with GCT and tumors from Sertoli–Leydig cells, while in ovarian adenocarcinomas and malignant tumors of other locations inhibin B secretion doesn’t differ from the control. The sensitivity of inhibin B in diagnostics of GCT was 93.5 %, in tumor from Sertoli–Leydig cells – 81.3 % with specificity – 100 %.
Conclusion. Inhibin B is an effective biomarker of GCT and ovarian tumors from Sertoli–Leydig cells, which results must be interpreted according the functional state of the ovaries.
About the Authors
N. V. Lyubimova
N.N. Blokhin National Medical Research Center of Oncology, Ministry of Health of Russia
Russian Federation
24 Kashirskoe Shosse, Moscow 115478
Russian Federation
24 Kashirskoe Shosse, Moscow 115478
A. M. Beishembaev
S.B. Daniyarova Kyrgyz State Medical Institute for Retraining and Further Training, Ministry of Health of the Kyrgyz Republic
Kyrgyzstan
144a Bokonbaeva St., Bishkek 720064
Kyrgyzstan
144a Bokonbaeva St., Bishkek 720064
Yu. S. Timofeev
N.N. Blokhin National Medical Research Center of Oncology, Ministry of Health of Russia
Russian Federation
24 Kashirskoe Shosse, Moscow 115478
Russian Federation
24 Kashirskoe Shosse, Moscow 115478
N. E. Kushlinskii
N.N. Blokhin National Medical Research Center of Oncology, Ministry of Health of Russia
Russian Federation
24 Kashirskoe Shosse, Moscow 115478
Russian Federation
24 Kashirskoe Shosse, Moscow 115478
References
1. Bryk S., Farkkila A., Bützow R. et al. Clinical characteristics and survival of patients with an adult-type ovarian granulosa cell tumor: a 56-year single-center experience. Int J Gynecol Cancer 2015;25(1):33–41. DOI: 10.1097/IGC.0000000000000304.
2. Davydov M.I. Lectures on gynecological oncology. Moscow: MEDpress-inform, 2009. Pp. 288–322. (In Russ.).
3. Kozachenko V.P. Sex cord stromal tumors. Onkoginekologiya = Oncogynecology 2015;(4):41–7. (In Russ.).
4. Liang L., Menzin A., Lovecchio J.L., Navarro M.D. Ovarian Sertoli-Leydig cell tumor with predominant heterologous mucinous differentiation and foci of hepatocytic differentiation: case report and review of the literature. Ann Clin Lab Sci 2015;45(3):348–51.
5. Tretarre B., Molinie F., Woronoff A.S. et al. Ovarian cancer in France: trends in incidence, mortality and survival, 1980– 2012. Gynecol Oncol 2015;139(2):324–9. DOI: 10.1016/j.ygyno.2015.09.013.
6. Seagle B.L., Ann P., Butler S., Shahabi S. Ovarian granulosa cell tumor: A National Cancer Database study. Gynecol Oncol 2017;146(2):285–91.
7. Levin G., Zigron R., Haj-Yahya R. et al. Granulosa cell tumor of ovary: A systematic review of recent evidence. Eur J Obstet Gynecol Reprod Biol 2018;225:57–61. DOI: 10.1016/j.ejogrb.2018.04.002.
8. Rey R., Sabourin J.C., Venara M. et al. Anti-Müllerian hormone is a specific marker of sertoli- and granulosa-cell origin in gonadal tumors. Hum Pathol 2000;31(10):1202–8. DOI: 10.1053/hupa.2000.18498.
9. Robertson D.M., Stephenson T., Pruysers E. et al. Inhibins/activins as diagnostic markers for ovarian cancer. Mol Cell Endocrinol 2002;191(1):97–103. DOI: 10.1016/s0303-7207(02)00060-6.
10. Färkkilä A., Haltia U.M., Tapper J. et al. Pathogenesis and treatment of adult-type granulosa cell tumor of the ovary. Ann Med 2017;49(5):435–47. DOI: 10.1080/07853890.2017.1294760.
11. Cherepanova E.V., Laktionov K.P., Anurova O.A. et al. Clinical and morphological features of ovarian tumors from Sertoli–Leydig cells. Opukholi zhenskoy reproduktivnoy sistemy = Tumors of the Female Reproductive System 2010;(4):83–8. (In Russ.).
12. Alam K., Maheshwari V., Rashid S. et. al. Bilateral Sertoli–Leydig cell tumor of the ovary: a rare case report. Indian J Pathol Microbiol 2009;52(1):97–9. DOI: 10.4103/0377-4929.44981.
13. Cabrera-Cantu F., Urrutia-Osorio M., Valdez-Arellano F. et al. Sertoli–Leydig cell tumor in a 12-year-old girl: a review article and case report. Arch Gynecol Obstet 2014;290(4):791–6. DOI: 10.1007/s00404-014-3293-6.
14. Schneider D.T., Orbach D., Cecchetto G. et al. Ovarian Sertoli–Leydig cell tumours in children and adolescents: an analysis of the European Cooperative Study Group on Pediatric Rare Tumors (EXPeRT). Eur J Cancer 2015;51(4):543–50. DOI: 10.1016/j.ejca.2014.11.013.
15. Burger H.G., Robertson D.M., Cahir N. et al. Caracterization of inhibin immunoreactivity in post-menopausal women with ovarian tumors. Clin Endocrinol 1996;44(4):413–8. DOI: 10.1046/j.1365-2265.1996.627450.x.
16. Burger H.G., Fuller P.J., Chu S. et al. The inhibins and ovarian cancer. Mol Cell Endocrinol 2001;180(1–2):145–8. DOI: 10.1016/s0303-7207(01)00519-6.
17. Groome N.P., Illingworth P.J., O’Brien M. et al. Measurement of dimeric inhibin B throughout the human menstrual cycle. J Clin Endocrinol Metab 1996;81(4):1401–5. DOI: 10.1210/jcem.81.4.8636341.
18. Beishembaev A.M., Lyubimova N.V., Abaev V.M. et al. The use of inhibin B in relapses of granulosa cell tumors of the ovaries. Opukholi zhenskoy reproduktivnoy sistemy = Tumors of the Female Reproductive System 2010;(3): 68–72. (In Russ.).
19. Lyubimova N.V., Beishembaev A.M., Kushlinskii D.N. etal. Granulosa cell tumors of the ovary and inhibin B. Byulleten’ eksperimental’noy biologii i meditsiny = Bulletin of Experimental Biology and Medicine 2010;150(11): 567–70. (In Russ.).
20. Zhordania K.I., Kerzhkovskaya N.S., Payanidi U.G. et al. Granulosa cell tumors of the ovary. Onkoginekologiya = Oncogynecology 2014;(2):33–41. (In Russ.).
21. Haltia U.M., Hallamaa M., Tapper J. et al. Roles of human epididymis protein 4, carbohydrate antigen 125, inhibin B and anti-Müllerian hormone in the differential diagnosis and follow-up of ovarian granulosa cell tumors. Gynecol Oncol 2017;144(1):83–9. DOI: 10.1016/j.ygyno.2016.11.018.
22. Mom C.H., Engelen M.J., Willemse P.H. Granulosa cell tumors of the ovary: the clinical value of serum inhibin A and B levels in a large single center. Gynecol Oncol 2007;105(2):365–72. DOI: 10.1016/j.ygyno.2006.12.034.
Review
For citations:
Lyubimova N.V., Beishembaev A.M., Timofeev Yu.S., Kushlinskii N.E. Inhibin B in stromal-cell ovarian tumors. Advances in Molecular Oncology. 2020;7(1):32-37. (In Russ.) https://doi.org/10.17650/2313-805X-2020-7-1-32-37
Views:
2216
Email this article 